Deucravacitinib-TNFi Combination Therapy for Difficult-to-Control Psoriatic Disease

Part of paid clinical trials in Dallas, Texas.

Sponsor
University of Texas Southwestern Medical Center
Study ID
NCT07280702
Phase
PHASE4
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Psoriatic Arthritis (PsA)

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

  • Deucravacitinib — DRUG
    Drug will be administered in tablet form.
  • Placebo — DRUG
    Drug will be administered in tablet form.

Study Details

The purpose of this research study is to determine the effectiveness of adding deucravacitinib to the participant's current Psoriatic Arthritis (PsA) treatment to see if it improves their symptoms and quality of life. This study is exploring a new treatment approach that may help improve control of psoriatic disease by targeting different parts of the disease process. By combining therapies that work together, the goal is to offer better symptom relief with fewer or more manageable side effects than some current treatments.

Key Dates

Start date
Apr 15, 2026
Status verified
Apr 2026
Primary completion
Dec 15, 2027
Completion
Dec 15, 2027

Study Design

Enrollment
128 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: established standard of care anti-TNF plus deucravacitinib
    Deucravacitinib will be administered in tablet form. Anti-TNF will be administered by injection.
  • Placebo Comparator: established standard of care anti-TNF plus placebo
    Placebo will be administered in tablet form. Anti-TNF will be administered by injection.

Primary Outcome Measure

Proportion of patients achieving a novel composite endpoint of BSA </= 1 AND SJC </= 1) OR (BSA </= 1 AND TJC </= 1) at 24 weeks [ Time Frame: 24 weeks ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
UT Southwestern Medical CenterDallasTexas75390
Joseph F Merola, MD MMSc
[email protected]
917-671-8192
Aleuna Lee, PhD, CCRC
[email protected]
214-645-8968

Find similar trials in Dallas, TX

By research site
UT Southwestern Medical Center· Dallas, TX

Related Studies